NCT03799744 2022-03-28
Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma
Institut Català d'Oncologia
Phase 1 Unknown
Institut Català d'Oncologia
Shanghai Zhongshan Hospital
Gustave Roussy, Cancer Campus, Grand Paris
British Columbia Cancer Agency